Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 28, 2007Blood

The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera

View Full Paper
Ask AI
Bookmark
Share

Authors

SDSabrina DupontDuke UniversityAMAline MasséCentre National de la Recherche ScientifiqueCJChloé JamesUniversité de Bordeaux

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Dupont et al. (2007) studied this question.

synapsesocial.com/papers/6a1bdfdf4ebd09f3dfa92445https://doi.org/10.1182/blood-2006-10-054940
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera2006 · 235 citations
  2. 2Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders2006 · 284 citations